Alzheimer’s drugs market to boost in both developed and developing region markets

The latest study by Transparency Market Research has shown that the world Alzheimer’s drugs market was mainly dominated by Allergan plc and Novartis AG in 2016, with their global market presence owing to acquisitions of leading emerging companies. In addition, the wide perspective for the Alzheimer’s drugs market in emerging countires, due to lack of awareness about the disease in some underdeveloped countries, has made these regions central for global drug makers of Alzheimer’s drugs.

Alzheimer’s drugs market in emerging countires is crucial  to drug makers due to lack of awareness of the disease.

However, players located in developed regions such as North America and Europe continue to remain likely to lead the global Alzheimer’s drugs market in the coming years due to the widespread availability of Alzheimer’s treatment channels in countries such as the U.S., Canada, the U.K., and Germany.Beyond Allergan and Novartis as mentioned abov, other key players in the global Alzheimer’s drugs market include Eisai Co Ltd, H Lundbeck A/S, Daiichi Sankyo Company Limited, Ono Pharmaceutical Co Ltd, Merz Holding GmbH & Co KG, and Johnson & Johnson.

Numbers-wise, the global Alzheimer’s drugs market is expected to exhibit a consistent 7.5% CAGR in the 2017-2025 forecast period. The market’s revenue was valued at more than US$3.6 bn in 2017 and is expected to rise to US$6.4 bn by 2025.

Memantine likely to dominate global alzheimer’s drugs market

By drug class, the global Alzheimer’s drugs market is segmented into cholinergic, memantine, combined drugs, and others. Of these, memantine is likely to remain the leading contributor to the global Alzheimer’s drugs market in the coming years, due primarily to the paucity of effective drug classes in several developing regions. Combined drug treatment is also likely to remain a key contributor to the global Alzheimer’s drugs market in the coming years due to the growing recognition of its efficacy and rising availability in developed countries.

North America is likely to remain the leading regional segment of the global Alzheimer’s drugs market in the coming years due to the presence of several leading players, which has made distribution easier in the region. The North America Alzheimer’s drugs market garnered revenue of US$1.7 bn in 2017 and is likely to rise to more than US$3 bn by 2025 at a steady CAGR of 7.3%. The Asia Pacific Alzheimer’s drugs market, on the other hand, is likely to exhibit the highest CAGR, at 8.6%, in the 2017-2025 forecast period, with the region expected to rise from a revenue valuation of US$1.1 bn to close to US$2.3 bn therein.

Growing prevalence of Alzheimer’s in developed countries will propel Alzheimer’s drugs market

The prime driver for the global Alzheimer’s drugs market is the rising prevalence of the disease in developed Western countries. Several neurodegenerative diseases have risen in prevalence in countries such as the U.S. in recent years, leading to steady government support for drug development. This has resulted in a highly conducive atmosphere for the Alzheimer’s drugs market in North America, leading to steady growth of the market in countries such as the U.S.

Nonetheless, the rising awareness about neurodegenerative diseases in developing regions such as Asia Pacific is likely owing to the global Alzheimer’s drugs market in the coming years. In several countries in Southeast Asia, consciousness about Alzheimer’s disease remains insufficient, which has led to unstable healthcare systems and unsupportive research infrastructure. The high prices of advanced Alzheimer’s drugs have also curb the Alzheimer’s drugs market in derdeveloping countries in Asia Pacific. The growing support for mental care infrastructure from governments in several developing Asia Pacific countries is thus likely to drive the Alzheimer’s drugs market in the region in the future.